arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Royalty Pharma plc

RPRX
$57.65 ▼ -0.88 (-1.50%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
29 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
88
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Royalty Pharma plc shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $25.7B
Dividend Yield 0.41%
Revenue Growth 16.5%
Op. Margin 19.7%
ROIC 1.5%
FCF / Share $1.64
Trailing P/E 1441.3x
Price / Book
FCF Yield 2.8%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

29-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$674.14M
↑ +16.5%
Net Income Profit after all expenses
$17.88M
↓ -40.7%
Operating Margin Operating profit as % of sales
19.7%
↓ -77.9% 99th
FCF / Share Free cash flow per share
$1.64
— -0.5%
Long-Term Debt Long-term obligations
$8.96B
— +0.1%
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
98
Financial Health
75
Cash Quality
92

Dividend History

Dividend / share · sourced from SEC filings
$0.80 Latest / share
+5.3% YoY
+38.7% 4-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 29 quarters